Published in Mol Cell Biol on December 01, 1998
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J (1999) 3.11
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell (2008) 2.71
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest (2003) 2.12
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev (2005) 1.94
PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Mol Cell Biol (2001) 1.85
BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol (2000) 1.80
CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood (2009) 1.74
Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res (2000) 1.74
An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2003) 1.69
AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med (2002) 1.65
SMRTe, a silencing mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear receptor corepressor. Proc Natl Acad Sci U S A (1999) 1.63
ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J (2006) 1.63
Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J (2001) 1.62
Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev (2006) 1.61
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery. Nat Struct Mol Biol (2011) 1.53
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev (2008) 1.51
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol (2001) 1.46
Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell (2007) 1.43
Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J (2000) 1.42
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol (2011) 1.40
The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol (2003) 1.38
Histone deacetylase-associating Atrophin proteins are nuclear receptor corepressors. Genes Dev (2006) 1.38
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. Proc Natl Acad Sci U S A (1999) 1.37
A novel role for helix 12 of retinoid X receptor in regulating repression. Mol Cell Biol (1999) 1.36
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia (2012) 1.35
Chromatin remodeling in cardiovascular development and physiology. Circ Res (2011) 1.34
The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol (2000) 1.33
Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol (2008) 1.29
Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood (2007) 1.29
P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL. EMBO J (2000) 1.25
mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol (2000) 1.24
Nuclear hormone receptor co-repressors: structure and function. Mol Cell Endocrinol (2011) 1.23
Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol (2001) 1.22
AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet (2008) 1.17
Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine. Mol Cell Biol (2005) 1.16
RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog (2011) 1.15
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A (2005) 1.14
Nuclear receptor corepressors. Nucl Recept Signal (2003) 1.14
Gene targeting reveals a crucial role for MTG8 in the gut. Mol Cell Biol (2001) 1.14
Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription. J Cell Biol (2000) 1.14
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
Atrophin proteins: an overview of a new class of nuclear receptor corepressors. Nucl Recept Signal (2008) 1.10
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci U S A (1999) 1.10
Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins. Proc Natl Acad Sci U S A (2002) 1.08
t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood (2008) 1.07
PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood (2012) 1.07
Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. Blood (2008) 1.06
Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription. Mol Cell Biol (2007) 1.06
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood (2014) 1.03
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature (2013) 0.99
Core binding factor at the crossroads: determining the fate of the HSC. J Cell Physiol (2010) 0.98
Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. Blood (2009) 0.98
Identification of AML1-ETO modulators by chemical genomics. Blood (2009) 0.97
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A (2009) 0.96
Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol (2002) 0.96
Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood (2014) 0.94
ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes. Mol Cell Biol (2008) 0.93
Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood (2011) 0.93
The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer (2004) 0.92
Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery. Mol Cell Biol (2009) 0.92
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol (2014) 0.92
Activation of ATM-dependent DNA damage signal pathway by a histone deacetylase inhibitor, trichostatin A. Cancer Res Treat (2007) 0.92
RUNX1: A microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci (2013) 0.91
PLZF is a negative regulator of retinoic acid receptor transcriptional activity. Nucl Recept (2003) 0.90
Epigenetic therapies in MDS and AML. Adv Exp Med Biol (2013) 0.90
The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell (2013) 0.90
Structural and functional analysis of the DEAF-1 and BS69 MYND domains. PLoS One (2013) 0.89
PDCD2 is essential for inner cell mass development and embryonic stem cell maintenance. Dev Biol (2010) 0.89
Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88
Aberrant CBFA2T3B gene promoter methylation in breast tumors. Mol Cancer (2004) 0.87
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics (2013) 0.87
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J (2005) 0.85
Mtg16/Eto2 contributes to murine T-cell development. Mol Cell Biol (2011) 0.85
Functional link between DNA damage responses and transcriptional regulation by ATM in response to a histone deacetylase inhibitor TSA. Cancer Res Treat (2007) 0.83
Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. J Mol Biol (2010) 0.83
Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence. EMBO J (2012) 0.83
Dynamics of epigenetic modifications in leukemia. Brief Funct Genomics (2011) 0.83
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev (2015) 0.82
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells Mol Dis (2007) 0.82
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation. Am J Clin Exp Urol (2014) 0.82
Novel RNA-binding properties of the MTG chromatin regulatory proteins. BMC Mol Biol (2008) 0.81
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. Epigenetics (2013) 0.81
Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation. Proc Natl Acad Sci U S A (2016) 0.80
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics (2015) 0.80
The human SIN3B corepressor forms a nucleolar complex with leukemia-associated ETO homologues. BMC Mol Biol (2008) 0.80
The leukemia associated ETO nuclear repressor gene is regulated by the GATA-1 transcription factor in erythroid/megakaryocytic cells. BMC Mol Biol (2010) 0.80
Functional interactions with Pit-1 reorganize co-repressor complexes in the living cell nucleus. J Cell Sci (2005) 0.80
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 16.57
Histone acetylation in chromatin structure and transcription. Nature (1997) 14.64
A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (1996) 12.64
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (1995) 11.53
A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (1995) 11.18
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (1996) 10.81
Histone acetylation and transcriptional regulatory mechanisms. Genes Dev (1998) 10.16
Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell (1996) 9.86
AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell (1996) 9.74
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 7.66
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 7.64
Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell (1997) 6.27
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell (1997) 5.83
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci U S A (1996) 5.61
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell (1996) 5.20
Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell (1995) 4.98
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev (1998) 4.78
Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature (1998) 4.68
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A (1996) 4.61
Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science (1998) 4.55
Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature (1998) 4.43
Histone acetyltransferase activity of yeast Gcn5p is required for the activation of target genes in vivo. Genes Dev (1998) 4.23
Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem (1997) 4.16
Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell (1998) 3.92
A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A (1998) 3.85
SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell (1998) 3.76
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol (1998) 3.51
Targeted recruitment of the Sin3-Rpd3 histone deacetylase complex generates a highly localized domain of repressed chromatin in vivo. Mol Cell Biol (1998) 3.51
RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae. Mol Cell Biol (1991) 3.22
The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J (1993) 3.00
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Critical residues for histone acetylation by Gcn5, functioning in Ada and SAGA complexes, are also required for transcriptional function in vivo. Genes Dev (1998) 2.76
SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.75
Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol (1997) 2.73
HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J Biol Chem (1996) 2.71
The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol (1995) 2.70
The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet (1993) 2.65
Conjunction dysfunction: CBP/p300 in human disease. Trends Genet (1998) 2.64
Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet (1997) 2.64
SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell (1998) 2.60
Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. EMBO J (1997) 2.58
A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol (1996) 2.47
The SAGA unfolds: convergence of transcription regulators in chromatin-modifying complexes. Trends Cell Biol (1998) 2.28
PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol (1994) 2.27
Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell (1996) 2.20
Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J (1998) 2.09
The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol (1998) 1.98
PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol (1994) 1.91
Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma. Mol Cell Biol (1996) 1.84
A large protein complex containing the yeast Sin3p and Rpd3p transcriptional regulators. Mol Cell Biol (1997) 1.83
Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene (1995) 1.83
The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A (1996) 1.78
The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene (1995) 1.78
AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood (1995) 1.77
Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol (1998) 1.69
The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol (1998) 1.58
The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol (1998) 1.55
Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol (1997) 1.52
Transcriptional repression by the SMRT-mSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol (1998) 1.51
Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex. Proc Natl Acad Sci U S A (1997) 1.41
Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A (1996) 1.28
AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol (1997) 1.27
Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression. Mol Cell Biol (1997) 1.26
A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol (1997) 1.22
Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol (1997) 1.11
Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Curr Top Microbiol Immunol (1996) 0.81
Acute promyelocytic leukemia: relieving repression induces remission. Blood (1998) 0.81
AML1 gene in human leukemias: dominant negative effects of the chimeric proteins over wild-type AML1. Jpn J Cancer Res (1997) 0.78
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
The sequence of the human genome. Science (2001) 101.55
Comparative genomics of the eukaryotes. Science (2000) 26.62
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell (2000) 11.10
The tripartite motif family identifies cell compartments. EMBO J (2001) 9.64
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (1992) 5.47
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol (2001) 4.92
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84
HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67
Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 4.67
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev (2000) 4.23
Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48
The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature (1999) 3.42
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15
Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem (1995) 3.13
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Applications of network BLAST server. Methods Enzymol (1996) 3.03
Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes Dev (1997) 3.01
A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A (2001) 2.93
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest (1999) 2.91
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development (1994) 2.83
The mechanism of action of thyroid hormones. Annu Rev Physiol (2000) 2.80
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood (1997) 2.72
A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control (2003) 2.67
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J (1997) 2.62
Association of an activator with an RNA polymerase II holoenzyme. Genes Dev (1995) 2.61
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Hormonal changes in the grains of rice subjected to water stress during grain filling. Plant Physiol (2001) 2.52
A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol Cell Biol (1996) 2.47
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature (1989) 2.46
Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Toxicol Appl Pharmacol (1997) 2.42
Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev (1997) 2.41